Regeneron Pharmaceuticals (REGN) Tax Provisions (2011 - 2026)

Regeneron Pharmaceuticals' Tax Provisions history runs 16 years deep, the most recent figure standing at $104.0 million for Q1 2026.

• In Q1 2026, Tax Provisions rose 8.0% year-over-year to $104.0 million; the TTM figure through Mar 2026 stood at $733.5 million (up 51.27% YoY), while the FY2025 annual figure was $725.8 million, up 97.6% from the prior year.
• Tax Provisions was $104.0 million for Q1 2026 at Regeneron Pharmaceuticals, down from $199.1 million in the prior quarter.
• In the past five years, Tax Provisions ranged from a high of $303.3 million in Q3 2025 to a low of -$21.3 million in Q1 2024.
• Historically, Tax Provisions has averaged $115.5 million across 5 years, with a median of $111.1 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Tax Provisions slumped 152.99% in 2024, then jumped 552.11% in 2025.
• A 5-year view of Tax Provisions shows it stood at $127.6 million in 2022, then tumbled by 109.4% to -$12.0 million in 2023, then jumped by 436.67% to $40.4 million in 2024, then jumped by 392.82% to $199.1 million in 2025, then sank by 47.76% to $104.0 million in 2026.
• The last three Tax Provisions figures came in at $104.0 million (Q1 2026), $199.1 million (Q4 2025), and $303.3 million (Q3 2025), per Business Quant data.